Close
Close

α-N-Cyc-Cer

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

A series of α-GalCer analogues with modified α-glycosidic linkages were tested for their ability to stimulate splenic NKT cell proliferation and cytokine production. These α-glycoside analogues included α-C-GalCer with a CH2 group in place of the glycosidic oxygen atom; a nonisosteric analogue that has one less CH2 group than α-C-GalCer in the link between the sugar and the sphingolipid (α-1C-GalCer); a compound with a rigid triple bond in the link between the sugar and sphingolipid (α-C-alkyne-GalCer); a variant bearing an ether oxygen atom in the linker (α-C-O-GalCer); and an aminocyclitol variant (α-N-Cyc-Cer). NKT cells respond to a variety of CD1d-restricted glycolipid antigens that are structurally related to the prototypic antigen, α-galactosylceramide (α-GalCer). A modified analogue of α-GalCer with a carbon-based glycosidic linkage (α-C-GalCer) has generated great interest because of its apparent ability to promote prolonged, Th1-biased immune responses.

  • TCR Vector Products

  • TCR Cell Products

  • TCR Viral Particles

Loading...
  • TCR Clone:
  • Host Species:
  • Epitope:
  • Allele:
  • Vector Type:
CAT Product Name Target Species TCR Clone Host Species Epitope Allele Vector Type Inquiry & Datasheet
TCR-YC1432 Human anti-α-N-Cyc-Cer T cell receptor (Vβ8.2), pCDTCR1 Vβ8.2 Human α-N-Cyc-Cer CD1d Lentiviral vector   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.
Copyright © 2024 Creative Biolabs. All Rights Reserved
Cart
    Go to checkout